Intuitive Surgical (ISRG) Stock Forecast (2026) - clearank.com
📈 ISRG trades at $401.65 with a Wall Street consensus buy rating and a median price target of $483.00.
💰 The company has consistently delivered strong revenue growth exceeding sector averages due to da Vinci system adoption.
⚠️ Over $127 million in insider stock sales have been recorded, signaling potential lack of confidence or strategic divestment.
🤖 Competing robotic surgical platforms from new and established players threaten ISRG's long-term market dominance.
📊 Historical data shows a $10,000 investment since 2016 grew to $50,332, outperforming the S&P 500 benchmark.
🔮 Monte Carlo simulations project a base case price of $631 by 2030 with a bear case downside to $269.
Bullish Signals
- ISRG has consistently delivered strong revenue growth that exceeds sector averages, driven by increasing adoption of its da Vinci surgical systems.
- The majority of Wall Street analysts maintain Buy ratings with a median price target of $483.00, indicating confidence in future performance and upside potential.
- Historical monthly performance trends show that a $10,000 investment in ISRG since September 2016 would be worth about $50,332 today, significantly outperforming the S&P 500.
Risk Factors
- Over $127 million in stock sales by insiders has been recorded, representing heavy insider selling that could indicate a lack of confidence in near-term stock appreciation.
- New entrants and established players are developing competing robotic surgical platforms, which could challenge ISRG's market dominance and pricing power over time.
Full Analysis
As of September 22, 2026, Intuitive Surgical (ISRG) trades at $401.65, with Wall Street analysts maintaining a consensus buy rating and a median price target of $483.00, implying approximately 20.3% upside potential. The company has demonstrated consistent revenue growth that exceeds sector averages, driven by the increasing adoption of its da Vinci surgical systems, which supports higher valuation multiples.
Despite the bullish analyst consensus, insider activity presents a notable cautionary signal, with over $127 million in stock sales recorded recently. This heavy insider selling could indicate a lack of confidence in near-term appreciation or represent strategic divestment by key personnel. Additionally, the competitive landscape is shifting as new entrants and established players develop competing robotic surgical platforms, posing potential long-term challenges to ISRG's market dominance and pricing power.
Long-term simulations suggest significant growth potential but also highlight volatility risks. CleaRank's 10-year Monte Carlo simulation projects a base case price near $631 by 2030 (a 1.6x increase from current levels), while the bear case scenario estimates a decline to around $269. Historical performance data indicates that a $10,000 investment in ISRG since September 2016 would have grown to approximately $50,332, significantly outperforming the S&P 500 benchmark which reached about $35,616 over the same period.
